Author response to "a response to 'personalised medicine and population health: breast and ovarian cancer'".
The author engages in further debate between numerous signatories of a letter who disputes that the author has put forward that the anticipated benefits of a personalised program for cancer prevention and screening are unwarranted. In the event that a cancer screening program is an effective means of mortality reduction, then the best strategy is universality. The benefit of a novel intervention should be evaluated prior to its introduction.